{
    "id": 3709,
    "name": "rectum mucinous adenocarcinoma",
    "source": "DOID",
    "definition": "A rectal adenocarcinoma that produces mucin. [url:https\\://www.ncbi.nlm.nih.gov/pmc/articles/PMC4110493/]",
    "currentPreferredTerm": null,
    "lastUpdateDateFromDO": "03/24/2020",
    "altIds": [
        
    ],
    "termId": "DOID:3709",
    "evidence": [
        {
            "id": 8152,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with microsatellite-stable mucinous rectal cancer harboring BRAF V600E and acquired MET amplification responded to the combination treatment of Xalkori (crizotinib) and Zelboraf (vemurafenib), resulting in a rapid clinical and metabolic response (PMID: 27325282).",
            "molecularProfile": {
                "id": 31714,
                "profileName": "BRAF V600E MET amp"
            },
            "therapy": {
                "id": 4648,
                "therapyName": "Crizotinib + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 3709,
                "name": "rectum mucinous adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6560,
                    "pubMedId": 27325282,
                    "title": "MET-Driven Resistance to Dual EGFR and BRAF Blockade May Be Overcome by Switching from EGFR to MET Inhibition in BRAF-Mutated Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27325282"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8153,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with microsatellite-stable mucinous rectal cancer harboring BRAF V600E eventually developed resistance to Vectibix (panitumumab) and Zelboraf (vemurafenib) combination therapy, potentially due to acquiring amplification of MET (PMID: 27325282).",
            "molecularProfile": {
                "id": 31714,
                "profileName": "BRAF V600E MET amp"
            },
            "therapy": {
                "id": 1717,
                "therapyName": "Panitumumab + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 3709,
                "name": "rectum mucinous adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 6560,
                    "pubMedId": 27325282,
                    "title": "MET-Driven Resistance to Dual EGFR and BRAF Blockade May Be Overcome by Switching from EGFR to MET Inhibition in BRAF-Mutated Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27325282"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "clinicalTrials": [
        {
            "nctId": "NCT03693846",
            "title": "Nivolumab and Ipilimumab in Mucinous Colorectal and Appendiceal Tumors",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1627,
                    "therapyName": "Ipilimumab + Nivolumab",
                    "synonyms": null
                }
            ]
        }
    ]
}